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Abstract
Background: Cytoreductive surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC) results in a number of
physiological changes with effects on the cardiovascular system, oxygen consumption and coagulation. The Critical
Care interventions required by this cohort of patients have not yet been quantified.
Methods: This retrospective audit examines the experience of a Specialist Tertiary Centre in England over an 18
month period (January 2009-June 2010) during which 69 patients underwent CRS and HIPEC. All patients were
extubated in the operating theatre and transferred to the Critical Care Unit (CCU) for initial post-operative
management.
Results: Patients needed to remain on the CCU for 2.4 days (0.8-7.8). There were no 30 day mortalities. The
majority of patients (70.1%) did not require post-operative organ support. 2 patients who developed pneumonia
post-operatively required respiratory support. 18 (26.1%) patients required vasopressor support with norepinephrine
with a mean duration of 13.94 hours (5-51 hours) and mean dose of 0.04 mcg/kg/min. Post-operative
coagulopathy peaked at 24 hours. A significant drop in serum albumin was observed.
Conclusion: The degree of organ support required post-operatively is minimal. Early extubation is efficacious with
the aid of epidural analgesia. Critical Care monitoring for 48 hours is desirable in view of the post-operative
challenges.
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Background
Pseudomyxoma peritonei is a rare epithelial neoplasm,
characterized by progressive accumulation of peritoneal
mucinous tumour deposition, usually originating from
the appendix. In Western populations there is an esti-
mated incidence of 1-2 per million a year [1].
Treatment of this condition with combined cytoreduc-
tive surgery (CRS) and hyperthermic intrapertioneal che-
motherapy (HIPEC) has been shown to improve both
patient survival and quality of life [2,3]. In this technique,
the chemotherapy agent is typically perfused within the
abdominal cavity for 90 minutes at a temperature of 42°C
achieving high peritoneal concentrations with limited
systemic absorption [4].
CRS and HIPEC has been depicted in some papers as a
high risk procedure with high levels of morbidity (22-39%)
[5], mortality (5%) [6] and prolonged hospital stays (up to
an average of 29 days)[7]. The most common complica-
tions include anastomatic leaks, intra-abdominal sepsis,
pancreatitis, intestinal fistula, renal failure and haematolo-
gical toxicity. Furthermore, some Oncologists that it is the
aggressive cytoreductive surgery alone that contributes to
improved outcomes and that HIPEC may not have an
impact on survival and simply adds unnecessary toxicity
[5]. Factors that have been shown to significantly improve
outcome include the peritoneal index (reflecting the dis-
ease burden) and the center in which the procedure is per-
formed (those with > 7 years experience performing
better) [8].
This complex procedure results in a number of phy-
siological changes with effects on the cardiovascular * Correspondence: cooks199@hotmail.com
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Care of these patients presents a significant challenge to
Anaesthetists and Critical Care Physicians. The Critical
Care interventions required by this cohort of patients
have not yet been quantified in the literature and this
study addresses this issue.
Methods
We conducted a retrospective audit examining the experi-
ence of a Specialist Tertiary Centre in the North West of
England, with 8 years experience of performing this proce-
dure, over an 18 month period (January 2009-June 2010).
During this period 69 patients underwent cytoreductive
surgery and HIPEC.
All patients received continuous thoracic epidural
analgesia with 0.125% bupivocaine and 2 mcg/ml fenta-
nyl. Regimes for induction and maintenance of anaes-
thesia were not standardized but determined by each
individual anaesthetist.
Patients underwent a series of peritonectomy procedures
to achieve complete cytoreduction. Peritoneal disease bur-
den was assessed intraoperatively using the Peritoneal
Cancer Index (PCI),[12] which scores 13 intra-abdominal
sites from 0 (no disease) to 3 (lesion size > 5 cm) giving a
possible range of scores from 0 to 39. HIPEC was only
undertaken in patients in whom complete cytoreduction
was achieved (a completeness of cytoreduction score < 1)
[13].
After cytoreduction, the abdominal cavity was filled with
1.5% dextrose peritoneal dialysis solution (1.5-3 litres),
then perfused at a temperature of 41.0°C to 42.5°C for
90 minutes. HIPEC was administered using either high
dose mitomycin C (35 mg/m
2 in three pulses) for tumours
of colorectal and appendiceal origin or doxorubicin
(15 mg/m
2) and cisplatinum (50 mg/m
2) for peritoneal
malignant mesothelioma.
Intra-operative fluids were guided by esophageal Dop-
pler monitoring and the patient’s hemodynamic status.
All patients were extubated in the operating theatre and
transferred to the Critical Care Unit (CCU) for initial
post-operative management. Nutritional support with
total parenteral nutrition (TPN) was commenced routi-
nely on arrival to CCU converting to nasojejunal enteral
nutrition after 2-3 days. Patient controlled epidural
analgesia (PCEA), intravenous proton pump inhibitor
(PPI) prophylaxis, nasogastric suction and low molecular
weight heparin for prevention of venous thrombosis were
given to all patients. Determination for the requirements
of organ support and further interventions were made by
the treating intensivist.
Analysis is based on data was gathered retrospectively
from the hospital’s peritoneal tumour service database
and digital CCU notes (MetaVision
® iMDsoft, Neuss,
Germany).
Results and discussion
The average age of the patients in this study was 53.3 years
(30-73) with 45 being female and 24 male. There was a
mean Apache II score of 13.6 ranging from 2 to 26.
The appendix was the most common site of the pri-
mary tumour (see table 1). The mean length of surgery
was 8.75 hours, including the administration of HIPEC,
with an observed mean PCI score of 10.5. Table 2 shows
the operative procedures performed.
Patients needed to remain on the Critical Care Unit
for 2.4 days (range 0.8-7.8 days) and length of hospital
stay was 13 days (8-36 days) (see table 3). There were
no 30 day mortalities.
Despite the physiological changes that occur in patients
undergoing cytoreductive surgery and HIPEC, the major-
ity of patients (70.1%) did not require post-operative
organ support. (see table 4). All patients were extubated
immediately post-operatively in theatre and no patient
required early re-intubation. 2 (3%) patients subsequently
required respiratory support due to the development of
post-operative pneumonia.
18 (26.1%) patients required vasopressor support with
norepinephrine. The mean duration of vasopressor
requirement was 13.94 hours (range 5-51 hours) with a
mean dose of 0.04 mcg/kg/min. Predictably, the patients
who had higher vasopressor requirements were those
who had significant post-operative complications. No
patients developed acute renal failure post-operatively.
Table 5 shows serial mean values of key blood para-
meters demonstrating the effects of cytoreductive surgery
and HIPEC on clotting (INR and aPTT), platelets, haemo-
globin and serum albumin and creatinine. There is a trend
towards coagulopathy peaking 24 hours post-operatively
although correction of abnormal coagulation with Fresh
Frozen Plasma was only indicated in 1 patient. 15 patients
required transfusion with Red Blood Cells in the post-
operative period on CCU.
There was a significant drop observed in serum albu-
min. All patients received immediate nutritional support
with TPN on their arrival to the CCU. Renal function,
reflected by no significant alterations in serum creatinine,
was well preserved.
T h e r ew a sal o wi n c i d e n c eo fs i g n i f i c a n tp o s t - o p e r a -
tive complications that necessitated interventions (see
Table 1 Primary site of tumour
Appendix 52
Colon 6
Caecum 3
Rectum 2
Ovary 2
Primary Peritoneal 1
Other/Unknown 3
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oped pneumonia post-operatively required respiratory
support via invasive positive pressure ventilation (IPPV)
and non-invasive ventilation (NIV) respectively.
One patient required the use of an intravenous glycerol-
tri-nitrate (GTN) infusion for 4 days for uncontrolled
hypertension. There were no surgical complications that
necessitated re-operation and no haematological toxicity
reactions to the HIPEC. Based upon our experience we
have created a checklist of the key peri-operative inter-
ventions for patients undergoing CRS and HIPEC (see
Figure 1).
Cytoreductive surgery and HIPEC results in a number of
physiological changes with effects on the cardiovascular
system, oxygen consumption and coagulation. Thus, there
are many potential challenges presented to Critical Care
Physicians in the immediate post-operative management.
There is an increase in airway pressure and a reduction
in functional residual capacity intra-operatively as the
administration of HIPEC causes elevation of the diaphragm
as a result of increased intra-abdominal pressure [9]. How-
ever, all of our patients were extubated immediately post-
operatively in the operating theatre with no complications
and there is no evidence in our data to suggest any signifi-
cant increase in post-operative oxygen requirements as a
direct result of HIPEC administration. Schmitz et al.
described 60% of their post-operative HIPEC patients
being transferred to the ICU ventilated with a median ven-
tilation of 3.7 hours although this period was 10.3 hours in
patients without epidural analgesia [10]. With the aid of
epidural analgesia our experience is that early extubation is
safe conferring the benefits of reduced periods of
ventilation.
In addition to the benefits of avoiding early post-opera-
tive ventilation, epidural analgesia is also associated with
improved patient satisfaction [14]. Furthermore, it reduces
the incidence of complications related to high dose intra-
venous opioids [15] and, in our experience, is valuable in
aiding the early mobilization of patients.
There are significant amounts of fluid loss (up to 4 litres
a day) in the first few days post CRS and HIPEC [11] and
adequate fluid resuscitation to ensure end-organ perfusion
is essential to prevent complications such as renal failure.
The administration of HIPEC increases cardiac output and
heart rate intra-operatively as a result of an increased
metabolic rate [10]. Vasopressor support may be required
for short periods particularly in the presence of thoracic
epidural analgesia, but our data suggest that HIPEC has
minimal cardiovascular sequelae in the post-operative per-
iod. This surgery is associated with significant protein
losses perioperatively [16] which, alongside albumin diffu-
sion into extravascular spaces as a consequence of intra-
operative cytokine release, result in a marked drop in
serum albumin and early administration of parenteral
nutrition is important.
Coagulopathy is a recognized complication of this sur-
gery [11]. It is probably dilutional in origin [17] due to the
high volume of fluid resuscitation and shift, although there
may be a direct effect from the HIPEC itself. Both our
own experience and that of Schimdt et al. is that restora-
tion of normal coagulation appears to have occurred
within 72 hours [10].
Sepsis is the leading cause of mortality post-operatively
and the nature of the procedure makes the patients at par-
ticularly high risk [18]. Haematological toxicity is a recog-
nized complication of HIPEC and has been reported in up
to 9% of patients [19]. Early recognition of post-operative
Table 3 Details regarding surgery and length of stays
Peritoneal Cancer Index (PCI) score 10.5 (0-33)
Length of surgery including HIPEC (hours) 8.75 (6.4-12.6)
Length of Critical Care Unit stay (days) 2.4 (0.8-7.8)
Length of Hospital stay (days) 13 (8-36)
Table 4 Organ support interventions required post-
operatively
Intervention Number of patients
Vasopressor support (Norepinephrine) 18 (26.1%)
Non-invasive ventilation 1 (1.5%)
Invasive Positive Pressure Ventilation 1 (1.5%)
Renal Replacement Therapy 0
Table 2 Operative procedures performed
Surgical procedure Number
performed
Appendicectomy 15
Total greater omentectomy 64
Lesser omentectomy 62
Cholecystectomy 40
Splenectomy 22
Right colonic resection 9
Left colonic resection 7
Small bowel resection 6
Liver surface ablation 24
Right hemidiaphragm peritonectomy or
ablation
22
Left hemidiaphragm peritonectomy or
ablation
12
Total abdominal hysterectomy 9
Bilateral oophorectomy 13
Unilateral oophorectomy 3
Partial hepatectomy 2
Nephrectomy 1
Distal pancreatectomy 1
Orchidectomy 1
Partial cystectomy 1
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bleeding and abscesses, is a key aspect of Critical Care
management.
Our centre has 8 years experience of performing
cytoreductive surgery and HIPEC. The low incidence of
need for organ support and other significant Critical
Care interventions is in part likely due to improved and
expert surgical technique which is associated with
reductions in morbidity and mortality [5,7]. Other stu-
dies have reported peri-operative mortality rates of 3%
[20] and 5% [6]. Furthermore, our patients had a shorter
mean length of total hospital stay (13 days) than many
centres (up to 29 days [7]) reflecting low complication
rates but may also in part be due to longer periods of
initial Critical Care monitoring.
The current cohort of patients undergoing this proce-
dure is relatively young with few co-morbidities. In
future, as the indications for HIPEC increase,[5,21] the
patient population may be older with significant co-
morbidities and their ability to tolerate the physiological
stresses would need to be re-evaluated.
Conclusion
Given the well described physiological abnormalities
that occur during cytoreductive surgery and HIPEC the
degree of organ support required is minimal. Early extu-
bation is efficacious with the aid of epidural analgesia.
Critical Care monitoring for 48 hours is still desirable in
view of the challenges of fluid management, low albu-
min state, coagulopathy and potential complications.
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Table 5 Mean values of key laboratory tests
Pre-operative Immediately post-op Day 1 post-op Day 3 post-op
Albumin (g/L) 44.2 22.7* 23.6* 28.2*
Creatinine (μmol/L) 88.3 82.5* 77.9* 68.6*
INR 1.10 1.34* 1.47* 1.24*
aPTT (secs) 29.6 31.0* 35.5* 33.2*
Platelets (x10
9/L) 306 238* 233* 219*
Haemoglobin (g/dL) 13.2 11.8* 10.7* 10.4*
(*) p < 0.05.
Table 6 Significant complications occurring the post-operative period
COMPLICATION NUMBER OF PATIENTS
Pneumonia 2 (2.9%)
Line sepsis 1 (1.5%)
Uncontrolled hypertension 1 (1.5%)
Arrhythmias 0
Acute Renal Failure 0
Surgical complications, such as intestinal fistula, requiring further surgery 0
Epidural anesthesia
Extubation immediately post-operatively
Direct transfer to Critical Care Unit (CCU)
Total Parenteral Nutrition (TPN) started immediately on arrival to CCU
Exquisite fluid status monitoring
Figure 1 A checklist for patients undergoing CRS and HIPEC.
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